57526-81-5

Basic information

• Product Name: PRENALTEROL
• Synonyms: PRENALTEROL;(s)-4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenol;(s)-pheno;cgp7760b;h133/22;Prenalterolprenalterol;[S,(-)]-1-(p-Hydroxyphenoxy)-3-(isopropylamino)-2-propanol;(S)-Prenalterol
• CAS NO: 57526-81-5
• Molecular Formula: C₁₂H₁₉NO₃
• Molecular Weight: 225.28
• EINECS: 260-791-5
• Product Categories: Aromatics;Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 57526-81-5.mol
• Article Data: 7

Chemical Properties

• Melting Point: 127-128°
• Boiling Point: 398℃
• Flash Point: 194℃
• Appearance: /
• Density: 1.118
• Vapor Pressure: 4.86E-07mmHg at 25°C
• Refractive Index: 1.538
• Storage Temp.: 2-8°C
• Solubility: Acetone (Slightly), DMSO (Slightly), Methanol (Slightly)
• PKA: pKa 9.5 (Uncertain);10.0 (Uncertain)
• CAS DataBase Reference: PRENALTEROL(CAS DataBase Reference)
• NIST Chemistry Reference: PRENALTEROL(57526-81-5)
• EPA Substance Registry System: PRENALTEROL(57526-81-5)

Safety Data

• Hazardous Substances Data: 57526-81-5(Hazardous Substances Data)

Usage

Description

Prenalterol, a β1-adrenergic agonist, is a pharmaceutical compound that plays a significant role in the treatment of various cardiovascular conditions. It works by stimulating the β1-adrenergic receptors, which are predominantly found in the heart, leading to an increase in heart contractility and rate. This action makes Prenalterol a valuable asset in managing heart-related issues.

Uses

Used in Pharmaceutical Industry:
Prenalterol is used as a cardiotonic agent for the treatment of heart failure and other conditions that require the enhancement of cardiac contractility. Its primary application is in the management of congestive heart failure, where it helps improve the heart's ability to pump blood effectively, thereby alleviating symptoms and improving the patient's quality of life.
Additionally, Prenalterol may be used in the treatment of certain arrhythmias, where its ability to increase heart rate can help regulate the rhythm of the heartbeat. Furthermore, it may also be utilized in the management of acute myocardial infarction (heart attack) to support the heart's function during the critical period following the event.

InChI:InChI=1/C12H19NO3/c1-9(2)13-7-11(15)8-16-12-5-3-10(14)4-6-12/h3-6,9,11,13-15H,7-8H2,1-2H3

Upstream product

• 57526-82-6 (2S)-1-<4-(benzyloxy)phenoxy>-3-<(1-methylethyl)amino>-2-propanol 
• 103-16-2 4-Benzyloxyphenol 
• 68430-29-5 (S)-5-hydroxymethyl-3-(methylethyl)oxazolidinone 
• 68430-35-3 (S)-3-isopropyl-5-p-toluenesulfonyloxymethyl-oxazolidin-2-one 
• 96854-69-2 (S)-5-(p-benzyloxy)phenoxymethyl-3-isopropyl-2-oxazolidinone 
• 86955-00-2 (S)-N-isopropyl-2,3-O-isopropylidene-D-glyceraldimine 
• 72223-70-2 (4S)-2,2-dimethyl-4-<<(1-methylethyl)(methylsulfonyl)amino>methyl>-1,3-dioxolane 
• 68430-26-2 [2S]-O-isopropylidene-3-isopropylamino-1,2-propanediol 
• 72223-71-3 (2S)-3-<(1-methylethyl)(methylsulfonyl)amino>-1,2-propanediol 
• 86955-02-4 (2S)-N-(1-methylethyl)-N-(methylsulfonyl)oxiranemethanamine 
• 86955-01-3 Acetic acid (S)-1-chloromethyl-2-(isopropyl-methanesulfonyl-amino)-ethyl ester 
• 72223-74-6 N-Isopropyl-N-((S)-2-methoxy-2-methyl-[1,3]dioxolan-4-ylmethyl)-methanesulfonamide 
• 72223-78-0 (2S)-1-<4-(benzyloxy)phenoxy>-3-<(1-methylethyl)(methylsulfonyl)amino>-2-propanol 
• 75-31-0 isopropylamine 

Downstream Products

• 86955-34-2 (S)-1-(4-{8-[4-((S)-2-Hydroxy-3-isopropylamino-propoxy)-phenoxy]-octyloxy}-phenoxy)-3-isopropylamino-propan-2-ol 
• 86955-37-5 (S)-1-(4-{12-[4-((S)-2-Hydroxy-3-isopropylamino-propoxy)-phenoxy]-dodecyloxy}-phenoxy)-3-isopropylamino-propan-2-ol 
• 86955-39-7 (S)-1-(4-{14-[4-((S)-2-Hydroxy-3-isopropylamino-propoxy)-phenoxy]-tetradecyloxy}-phenoxy)-3-isopropylamino-propan-2-ol 
• 86955-41-1 (S)-1-(4-{20-[4-((S)-2-Hydroxy-3-isopropylamino-propoxy)-phenoxy]-icosyloxy}-phenoxy)-3-isopropylamino-propan-2-ol 
• 86901-76-0 (S)-1-[4-(2-{2-[4-((S)-2-Hydroxy-3-isopropylamino-propoxy)-phenoxy]-ethoxy}-ethoxy)-phenoxy]-3-isopropylamino-propan-2-ol 
• 86955-28-4 (S)-1-(4-{2-[2-(2-{2-[4-((S)-2-Hydroxy-3-isopropylamino-propoxy)-phenoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-phenoxy)-3-isopropylamino-propan-2-ol 
• 86955-35-3 (S)-1-(4-{10-[4-((S)-2-Hydroxy-3-isopropylamino-propoxy)-phenoxy]-decyloxy}-phenoxy)-3-isopropylamino-propan-2-ol 
• 84057-96-5 flusoxolol 
• 86955-43-3 (S)-1-{4-[2-(2-{2-[4-((S)-2-Hydroxy-3-isopropylamino-propoxy)-phenoxy]-ethoxy}-ethoxy)-ethoxy]-phenoxy}-3-isopropylamino-propan-2-ol 

Relevant articles and documents

METHODS FOR DIAGNOSING, MONITORING AND TREATING NEUROLOGICAL DISEASES AND DISORDERS

In various aspects and embodiments provided are compositions and methods for identifying patients in need of improving cognition and/or treating a neurodegenerative disease in a patient and treating such patient.

Synthesis of (S)-β-Blockers from (S)-5-Hydroxymethyl-3-tert butyl-2-oxazolidinone or (S)-5-Hydroxymethyl-3-isopropyl-2-oxazolidinone

-

β1-Selective Adrenoceptor Antagonists. 1. Synthesis and β-Adrenergic Blocking Activity of a Series of Binary (Aryloxy)propanolamines

A series of binary (aryloxy)propanolamines has been prepared and examined in vitro and in vivo for β-adrenoreceptor blocking activity.These symmetrical compounds consist of two (S)-(phenyloxy)propanolamine pharmacophores coupled through alkylenedioxy or poly(oxyethylenedioxy) linking units of varying lengths.Examples of such binary compounds linked through the 2,2', 3,3', and 4,4' positions in the aromatic rings of the pharmacophores have been prepared.In vitro and in vivo test data indicate that the 2,2' compounds tend to be selective β2-adrenergic blocking agents, the 4,4' binaries tend to be selective β1-blocking agents, and those compounds with 3,3' linkages exhibit intermediate selectivities.One of the 4,4'-linked binary compounds, 4s, exhibited potent, cardioselective β-blockade in vivo, which was of short duration and was accompanied by a prolonged tachycardia.